Litcius/Paper detail

Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Florence Duffaud, Jean‐Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou‐Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valérie Laurence, Emmanuelle Bompas, Esma Saâda-Bouzid, Corinne Delcambre, François Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud

2023British Journal of Cancer31 citationsDOIOpen Access PDF

Topics & Concepts

RegorafenibMedicinePlaceboClinical endpointInternal medicineCohortAdverse effectSurgeryOncologyRandomized controlled trialColorectal cancerCancerPathologyAlternative medicineSarcoma Diagnosis and TreatmentManagement of metastatic bone diseaseCardiac tumors and thrombi
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study | Litcius